4//SEC Filing
EDGEMOND JAMES 4
Accession 0001636178-25-000010
CIK 0001082554other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 5:09 PM ET
Size
25.6 KB
Accession
0001636178-25-000010
Insider Transaction Report
Form 4
EDGEMOND JAMES
CFO AND TREASURER
Transactions
- Exercise/Conversion
Common Stock
2025-12-15$146.03/sh+3,517$513,588→ 11,659 total - Sale
Common Stock
2025-12-15$491.52/sh−160$78,644→ 11,499 total - Sale
Common Stock
2025-12-15$492.81/sh−840$413,958→ 10,659 total - Sale
Common Stock
2025-12-15$493.70/sh−561$276,968→ 10,098 total - Sale
Common Stock
2025-12-15$495.02/sh−360$178,206→ 9,738 total - Sale
Common Stock
2025-12-15$495.90/sh−520$257,869→ 9,218 total - Sale
Common Stock
2025-12-15$496.97/sh−200$99,395→ 9,018 total - Sale
Common Stock
2025-12-15$498.09/sh−395$196,745→ 8,623 total - Sale
Common Stock
2025-12-15$499.31/sh−240$119,835→ 8,383 total - Sale
Common Stock
2025-12-15$500.30/sh−241$120,573→ 8,142 total - Exercise/Conversion
Stock Option
2025-12-15−3,517→ 0 totalExercise: $146.03From: 2020-03-15Exp: 2027-03-15→ Common Stock (3,517 underlying)
Footnotes (11)
- [F1]This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.
- [F10]This transaction was executed in multiple trades at prices ranging from $498.88 to $499.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F11]This transaction was executed in multiple trades at prices ranging from $499.92 to $500.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]The amount of common stock beneficially owned by the Reporting Person in the Reporting Person's Form 4s filed November 5, 12 and 18, 2025 did not include 24 shares acquired by the Reporting Person on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan, which error caused the reporting person's common stock ownership to be underreported by 24 shares on such Form 4s. The amount of common stock beneficially owned by the Reporting Person in this Form 4 includes such shares.
- [F3]This transaction was executed in multiple trades at prices ranging from $491.19 to $491.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $492.28 to $493.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $493.35 to $494.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This transaction was executed in multiple trades at prices ranging from $494.52 to $495.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F7]This transaction was executed in multiple trades at prices ranging from $495.52 to $496.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F8]This transaction was executed in multiple trades at prices ranging from $496.59 to $497.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F9]This transaction was executed in multiple trades at prices ranging from $497.60 to $498.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
UNITED THERAPEUTICS Corp
CIK 0001082554
Entity typeother
Related Parties
1- filerCIK 0001636178
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 5:09 PM ET
- Size
- 25.6 KB